EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Pregnancy‑associated plasma protein‑A beyond the first trimester: Predictive value for adverse pregnancy outcomes (Review)

Maria Kavvalou, Ismini Tzanaki, Alexandros Velegrakis, Stavros Sifakis

Experimental and Therapeutic Medicine · 29.10.2026 · 32 (6) · 1-9

DOI: 10.3892/etm.2026.13348 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Experimental and Therapeutic Medicine, online erschienen am 29.10.2026. Verfasst von Maria Kavvalou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Harris Birthright Centre for Fetal Medicine, Fetal Medicine Research Institute, King's College Hospital, London SE5 8BB, United Kingdom. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pregnancy-associated plasma protein-A (PAPP-A) is a placentally-derived metalloproteinase that serves a key role in trophoblast invasion and fetal growth through the regulation of insulin-like growth factor bioavailability. Since its introduction into first-trimester aneuploidy screening, low maternal serum PAPP-A concentrations have been consistently associated with adverse pregnancy outcomes, including preeclampsia, preterm birth, fetal growth restriction, low birth weight and stillbirth. Although the clinical importance of reduced first-trimester PAPP-A concentrations is well established, the predictive value of PAPP-A measurements beyond the first trimester, particularly during the second trimester, remains less clearly defined. The present review summarizes the current research regarding the association between maternal serum PAPP-A concentrations throughout pregnancy and adverse obstetric outcomes, with a particular emphasis on second-trimester findings. Available evidence suggests that persistently low maternal serum PAPP-A concentrations from the first into the second trimester are associated with placental dysfunction-related complications. However, despite statistically significant associations, the predictive performance of PAPP-A as a standalone biomarker remains limited. Future prospective studies are required to determine whether incorporating second-trimester PAPP-A into multimarker prediction models can improve risk stratification, clinical decision-making and pregnancy outcomes.

Schlagwörter

Stichwörter der Autor:innen

FGRPAPP-APElow birth weightpreterm birthstillbirth

Autor:innen und Institutionen

  • Harris Birthright Centre for Fetal Medicine, Fetal Medicine Research Institute, King's College Hospital, London SE5 8BB, United Kingdom.
  • Department of Obstetrics and Gynecology, University Hospitals Dorset NHS Foundation Trust, Royal Bournemouth Hospital, Bournemouth BH7 7DW, United Kingdom.
  • Department of Obstetrics and Gynecology, University Hospital of Heraklion, Medical School, University of Crete, Heraklion 71500, Greece.
  • Mitera Kritis Hospital, Hellenic Healthcare Group, Heraklion 71202, Greece.

Zitieren

APA

Kavvalou, M., Tzanaki, I., Velegrakis, A., & Sifakis, S. (2026). Pregnancy‑associated plasma protein‑A beyond the first trimester: Predictive value for adverse pregnancy outcomes (Review). Experimental and Therapeutic Medicine, 32(6), 1-9. https://doi.org/10.3892/etm.2026.13348

Vancouver

Kavvalou M, Tzanaki I, Velegrakis A, Sifakis S. Pregnancy‑associated plasma protein‑A beyond the first trimester: Predictive value for adverse pregnancy outcomes (Review). Experimental and Therapeutic Medicine. 2026;32(6):1-9. doi:10.3892/etm.2026.13348

BibTeX
@article{Kavvalou2026,
  author = {Kavvalou, Maria and Tzanaki, Ismini and Velegrakis, Alexandros and Sifakis, Stavros},
  title = {Pregnancy‑associated plasma protein‑A beyond the first trimester: Predictive value for adverse pregnancy outcomes (Review)},
  journal = {Experimental and Therapeutic Medicine},
  year = {2026},
  volume = {32},
  number = {6},
  pages = {1--9},
  doi = {10.3892/etm.2026.13348}
}
Kostenlos starten →